# AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease

> **NCT00396201** · PHASE2 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 22 (actual)

## Conditions studied

- Hodgkin's Disease

## Interventions

- **DRUG:** G-CSF Plus Plerixafor

## Key facts

- **NCT ID:** NCT00396201
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2006-10
- **Final completion:** 2008-01
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2014-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00396201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00396201, "AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT00396201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*